Drug Type Monoclonal antibody |
Synonyms ICT 21, ICT-21 |
Target |
Mechanism BTN3A1 inhibitors(butyrophilin subfamily 3 member A1 inhibitors), T lymphocytes inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | FR | Imcheck Therapeutics SASStartup | - |